Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease

Rebecca H Haberman; Ramin Herati; David Simon; Marie Samanovic; Rebecca B. Blank; Michael Tuen; Sergei Koralov; Raja Atreya; Koray Tascilar; Joseph Allen; Rochelle Castillo; Amber Cornelius; Paula Rackoff; Gary Solomon; Samrachana Adhikari; Natalie Azar; Pamela Rosenthal; Peter Izmirly; Jonathan Samuels; Brian Golden; Soumya Reddy; Markus F. Neurath; Steven B. Abramson; Georg Schett; Mark J Mulligan; Jose U Scher.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-21256917

Documentos relacionados

  1. Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease.
  2. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.
  3. Innate Immunity in Protection and Pathogenesis During Coronavirus Infections and COVID-19.
  4. Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8<sup>+</sup> T cell responses post SARS-CoV-2 infection.
  5. mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8<sup>+</sup> T cell responses.